Monte Rosa Therapeutics and Novartis Partner on Degrader Development
CompanyDeals

Monte Rosa Therapeutics and Novartis Partner on Degrader Development

Fovinaciclib CDK4/6 Breaks Ground in Breast‑Cancer Therapy
Drug

Fovinaciclib CDK4/6 Breaks Ground in Breast‑Cancer Therapy

Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine
CompanyDrug

Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine

BioRay Biopharmaceutical Secures NMPA Approval for BGM0504 in Overweight/Obesity Trials
Drug

BioRay Biopharmaceutical Secures NMPA Approval for BGM0504 in Overweight/Obesity Trials

Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development
CompanyDeals

Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development

Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application
Drug

Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application

Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA
CompanyDeals

Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA

ZSCO Invests 790 m RMB in Guobang Pharma, Launches Strategic Partnership
CompanyDeals

ZSCO Invests 790 m RMB in Guobang Pharma, Launches Strategic Partnership

CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials
CompanyDrug

CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials

Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis
CompanyDrug

Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
CompanyDeals

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor

Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B
Drug

Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B